Prothena Q3 net loss $36.5M, nine-month loss $222.5M on charges; pipeline advances

PROTHENA CORP PUBLIC LTD CO

2025-Q3 EPS reported -$4.13 revenue$9,663,000

Net loss for Q3 2025 was $36.5M ($0.68/sh) vs $59.0M ($1.10/sh) in Q3 2024; nine-month loss $222.5M ($4.13/sh) vs $64.4M ($1.20/sh).
Revenue fell to $2.4M in Q3 2025 from $1.0M in Q3 2024; nine-month revenue $9.7M vs $133.0M primarily from BMS collaboration.
Cash and equivalents $331.7M; no debt. FY2025 guidance: net cash used $170-178M, year-end cash ~$298M midpoint.
Roche to initiate Phase 3 PARAISO prasinezumab trial for Parkinson's by end 2025; Novo Nordisk started Phase 3 CLEOPATTRA for coramitug in ATTR-CM.
EGM on Nov 19 to vote on share capital reduction to support potential 2026 share redemption program; up to $105M in clinical milestones by end 2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.